Physician profile
David G Morris
NPI 1477595643
$5,539.15
in general payments reported to CMS, 2019-2025
49 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $203 · 2021: $207 · 2022: $806 · 2023: $1,131 · 2024: $1,170 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.75 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $621.85 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Astellas Pharma US INC | $567.71 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Pfizer INC. | $316.63 | 2019-2025 | |
| Gilead Sciences, INC. | $310.94 | 2019-2025 | Trodelvy |
| Celgene Corporation | $294.29 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $276.28 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $256.32 | 2022-2025 | |
| Octapharma USA, INC. | $213.02 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Abbvie INC. | $192.79 | 2019-2025 | |
| Beigene USA, INC. | $185.44 | 2021-2025 | Brukinsa |
| Incyte Corporation | $184.12 | 2019-2025 | Monjuvi, Jakafi |
| Genzyme Corporation | $155.42 | 2019-2025 | |
| Exelixis INC. | $152.52 | 2024-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $134.22 | 2019-2025 | Enhertu, Imfinzi |
| Asd Specialty Healthcare, LLC | $115.85 | 2019 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $115.75 | 2019 | |
| Merck Sharp & Dohme LLC | $110.91 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $106.30 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $98.19 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Genentech USA, INC. | $93.59 | 2021-2025 | Polivy, Itovebi |
| Deciphera Pharmaceuticals INC. | $88.74 | 2023-2025 | Qinlock, Tgct |
| Myriad Genetic Laboratories, INC. | $86.63 | 2022 | |
| Kite Pharma, INC. | $77.22 | 2022-2025 | Yescarta |
| Array Biopharma INC | $68.71 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Daiichi Sankyo INC. | $66.61 | 2022-2025 | Injectafer, Enhertu |
| Puma Biotechnology, INC. | $59.57 | 2022-2025 | |
| Adc Therapeutics America, INC. | $54.10 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.17 | 2022-2025 | |
| Seagen INC. | $52.84 | 2019-2023 | Adcetris |
| Lilly USA, LLC | $38.62 | 2024-2025 | Jaypirca, Verzenio |
| Emd Serono, INC. | $35.51 | 2025 | |
| Blueprint Medicines Corporation | $34.50 | 2022 | |
| Ucb, INC. | $33.78 | 2023 | Nayzilam |
| Jazz Pharmaceuticals INC. | $27.45 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $26.65 | 2023 | Libtayo |
| Fresenius Kabi USA, LLC | $22.49 | 2025 | Stimufend |
| Cti Biopharma Corp. | $20.93 | 2022 | |
| Beone Medicines USA, INC. | $20.69 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2025 | Ninlaro |
| Amgen INC. | $17.41 | 2023 | Kyprolis |
| Ipsen Biopharmaceuticals, INC | $17.11 | 2024 | Somatuline Depot, Onivyde |
| Eisai INC. | $16.46 | 2022 | |
| Dendreon Pharmaceuticals LLC | $15.00 | 2025 | Provenge |
| Karyopharm Therapeutics INC. | $14.98 | 2023 | Xpovio |
| Rigel Pharmaceuticals, INC. | $14.80 | 2024 | Tavalisse, Rezlidhia |
| Coherus Oncology, INC. | $13.78 | 2022 | |
| Mirati Therapeutics, INC. | $13.52 | 2023 | Krazati |
| Apellis Pharmaceuticals, INC. | $13.41 | 2023 | Empaveli |
| Secura Bio, INC. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.